Epidemiological and molecular aspects of ovarian cancer risk
- PMID: 11216917
- PMCID: PMC12164990
- DOI: 10.1007/s004320000153
Epidemiological and molecular aspects of ovarian cancer risk
Abstract
In Western and Northern Europe, as well as in the United States, ovarian cancer represents the third most frequent cancer of the female genital tract with an estimated 191,000 newly diagnosed cases per year worldwide. Due to its insidious onset, the disease is diagnosed in 70% of cases in an advanced stage. Consequently, ovarian cancer is the fifth leading cause of cancer-related deaths in women. Epidemiological and molecular studies reviewed here have identified demographic, geographic, molecular, genetic, endocrine, dietary, and environmental factors, which affect the risk of developing ovarian cancer: ethnic background, tumor suppressor gene mutations in the germline, positive family history, number of full-term pregnancies [odds ratio (OR): 0.17; 95% confidence interval (CI): 0.05-0.54], time spent breast feeding, oral contraceptive use [OR: 0.23; 95% CI: 0.1-0.50], unexplained infertility (OR: 2.64; 95% CI: 1.10-6.35), tubal ligation and prior hysterectomy (OR: 0.5; 95% CI: 0.2-0.9), dietary factors and obesity (OR: 1.7; 95% CI: 1.1-2.8). This knowledge provides the objective basis for an individual risk assessment for women, which should lead to sophisticated counseling and prevention. It should also help to individualize the therapeutic approach in the event that disease is diagnosed.
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866378 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2. Cochrane Database Syst Rev. 2016. PMID: 26930463 Free PMC article.
-
Optimal primary surgical treatment for advanced epithelial ovarian cancer.Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2. Cochrane Database Syst Rev. 2011. PMID: 21833960 Free PMC article.
Cited by
-
The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer.Med Oncol. 2012 Dec;29(5):3409-15. doi: 10.1007/s12032-012-0275-z. Epub 2012 Jun 20. Med Oncol. 2012. PMID: 22714061
-
Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.J Mol Med (Berl). 2015 Apr;93(4):427-38. doi: 10.1007/s00109-014-1228-0. Epub 2014 Nov 21. J Mol Med (Berl). 2015. PMID: 25411027
-
Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer.Int J Gynecol Cancer. 2009 May;19(4):531-9. doi: 10.1111/IGC.0b013e3181a41613. Int J Gynecol Cancer. 2009. PMID: 19509547 Free PMC article.
-
Serum CA125 concentration has inverse correlation with metabolic syndrome.J Korean Med Sci. 2011 Oct;26(10):1328-32. doi: 10.3346/jkms.2011.26.10.1328. Epub 2011 Oct 1. J Korean Med Sci. 2011. PMID: 22022186 Free PMC article.
-
High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma.Virchows Arch. 2014 Apr;464(4):443-52. doi: 10.1007/s00428-014-1536-3. Epub 2014 Jan 24. Virchows Arch. 2014. PMID: 24458516
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical